A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial

627 POSTER UFT/LV combined with oxaliplatin (TEGAFOX) or with irinotecan (TEGAFIRI) as first-line treatment for metastatic colorectal cancer patients (pts). results of a randomized phase II I.T.M.O. study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80923-1 ◽

2005 ◽

Vol 3 (2) ◽

pp. 177

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Faculty of 1000 evaluation for FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718009648.793485773 ◽

2013 ◽

Author(s):

Yiqian Nancy You ◽

Craig Messick

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases â a CESAR phase II study including pharmacokinetic, biomarker, and imaging data

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cp202109 ◽

2014 ◽

Vol 52 (08) ◽

pp. 642-652 ◽

Cited By ~ 5

Author(s):

Klaus Mross ◽

Max Scheulen ◽

Dirk Strumberg ◽

Jan Kuhlmann ◽

Friederike Kanefendt ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Cancer Patients ◽

Phase Ii Study ◽

Line Treatment ◽

Imaging Data ◽

First Line ◽

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)

Annals of Oncology ◽

10.1093/annonc/mdt165 ◽

2013 ◽

Vol 24 (8) ◽

pp. 2062-2067 ◽

Cited By ~ 67

Author(s):

L. Fornaro ◽

S. Lonardi ◽

G. Masi ◽

F. Loupakis ◽

F. Bergamo ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Cited By ~ 1

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Cited By ~ 83

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies

Annals of Oncology ◽

10.1093/annonc/mdw335.14 ◽

2016 ◽

Vol 27 ◽

pp. iv43

Author(s):

D. Rossini ◽

M. Casagrande ◽

R. Moretto ◽

F. Loupakis ◽

C. Cremolini ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Pooled Analysis ◽

Line Treatment ◽

Targeted Agents ◽

First Line ◽

Safety And Efficacy ◽

Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)

Annals of Oncology ◽

10.1093/annonc/mdy281.154 ◽

2018 ◽

Vol 29 ◽

pp. viii202

Author(s):

A. De Stefano ◽

G. Nasti ◽

A. Febbraro ◽

G. Rosati ◽

F. Giuliani ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽